F2RL2 and ovarian carcinoma: In breast cancer, F2RL2 promotes tumor growth and metastasis by activating the thrombin signaling pathway, whereas in ovarian cancer, it accelerates tumor progression by modulating immune evasion mechanisms, such as modulating immune cell infiltration [28].